Home Contact Center Add this

Let's meet

AACR Annual Meeting 2015

AACR Annual Meeting 2015
April 18-22, 2015ALL EVENTS

13 January 2015 / international

Debiopharm Diagnostics leads investment round in GenePOC with Emerillon Capital [Read more]

12 January 2015 / international

Debiopharm Group regains full rights to Alisporivir program [Read more]

08 January 2015 / international

FDA Grants Fast Track designation to Debiopharm Group’s antibiotic Debio 1450 [Read more]


18 November 2014

Debiopharm Group™ presents advances of two key oncology clinical programs at the 26th EORTC-NCI-AACR symposium in Barcelona [Read more]

07 October 2014

Debiopharm Group™ Announces Progress in Phase I Single and Multiple Ascending Dose Study of Debio 1450, its Potent Anti-staphylococcal Agent [Read more]

30 September 2014

Trelstar® Six-Month Dosing for Prostate Cancer Patients Launches in Canada [Read more]


18 December 2014

Debiopharm Investment, Ardian, Nixdorf Foundation and Bernis today acquire Eco Delta solar activities [Read more]

27 November 2014

Debiopharm Investment becomes a minority shareholder in Haut-Lac International Bilingual School in St-Légier (VD) [Read more]

17 November 2014

Coorpacademy, établi à l’EPFL et l’un des leaders des MOOCs à destination des entreprises, lève 3,2 millions d’euros auprès de Debiopharm Investment et du fonds français NextStage [Read more]


18 March 2015

Activity of Debio1452, a FabI inhibitor with potent activity against S. aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains. [Read more]

10 February 2015

Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer [Read more]

21 November 2014

Preclinical activity of Debio 1347, an oral selective FGFR1, 2, 3 inhibitor, in models harboring FGFR alterations [Read more]


bulle slideshow group

bulle slideshow diagnostics

bulle slideshow international

bulle slideshow investment

bulle slideshow research